Boston Scientific Announces Availability of New Connector System Designed to Simplify the Implant Procedure for Cardiac Devices

PARIS, March 24, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced
European commercial availability of the Company's new cardiac rhythm
management connector system, which consists of the ENDOTAK RELIANCE(R) 4-SITE
defibrillation lead and compatible COGNIS(R) cardiac resynchronization
therapy defibrillators (CRT-Ds) and TELIGEN(R) implantable cardioverter
defibrillators (ICDs). The system is designed to simplify the implant
procedure by combining three terminals into one integrated connector, further
reducing the volume of the world's smallest and thinnest high-energy CRT-Ds
and ICDs. The Company announced CE Mark and first implant of this system in
May 2009.

"Boston Scientific commissioned a prospective, multi-center
observational clinical study involving more than 400 patients to extensively
evaluate the 4-SITE system and to demonstrate appropriate clinical
performance before making it broadly available in Europe," said Poul Erik
Bloch Thomsen, M.D., Ph.D., Gentofte University Hospital, Copenhagen,
Denmark. "The study examined both shocking and pacing performances and showed
that the 4-SITE system increased the simplicity and overall efficiency of the
implant procedure, and further reduced the already low likelihood of
complications arising from connections being reversed."

"The launch of the ENDOTAK RELIANCE 4-SITE lead system is
another significant milestone for our Company, which spans from the first
human implant of the ICD 30 years ago to manufacturing the smallest, thinnest
high energy devices today," said Fred Hrkac, President of Europe, Middle East
and Africa (EMEA) for Boston Scientific. "This system represents the next
advance for the ENDOTAK RELIANCE lead family, which has demonstrated
reliability in more than 400,000 implants worldwide."

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estimate," "intend" and similar
words. These forward-looking statements are based on our beliefs, assumptions
and estimates using information available to us at the time and are not
intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements regarding
clinical trials, scientific activities, product performance, competitive
offerings and growth investment. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual results
could vary materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could affect our
ability to implement our business strategy and may cause actual results to
differ materially from those contemplated by the statements expressed in this
press release. As a result, readers are cautioned not to place undue reliance
on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A-
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
thereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

CONTACT: Geraldine Varoqui, Director International Public Relation, Tel: +49-2102-489-461, Mob: +49-170-782-85-58, varoquig at bsci.com